Non-Alcoholic Steatohepatitis (NASH) Treatment Market By Drug Class (THR-β Agonists, GLP-1 Receptor Agonists, Dual Incretin Therapies, FGF21 Analogues, PPAR Agonists, Glucagon/GLP-1 Dual Agonists, Supportive Metabolic Therapies); By Disease Stage (Noncirrhotic MASH/NASH with F2 Fibrosis, Noncirrhotic MASH/NASH with F3 Fibrosis, Compensated Cirrhosis, High-Risk MASLD Patients Under Evaluation); By Route of Administration (Oral Therapies, Injectable Therapies); By Treatment Setting (Hepatology Clinics, Gastroenterology Clinics, Endocrinology & Diabetes Clinics, Obesity & Weight-Management Centers, Hospitals, Specialty Liver Centers); By Patient Risk Group (Patients with Type 2 Diabetes, Patients with Obesity, Patients with Moderate-to-Advanced Fibrosis, Patients with Cardiometabolic Risk, Patients Referred Through Abnormal Liver Tests); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Non-Alcoholic Steatohepatitis Treatment Market: Fibrosis-Defined Approvals, GLP-1 Competition, and Testing Capacity Redraw MASH Care

The Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market was valued at USD 8.75 billion in 2025 and is projected to reach USD 46.87 billion by 2032, growing at a CAGR of 27.1%, according to Strategic Market Research.

 

Although MASH is replacing NASH in current clinical terminology, NASH remains widely used in drug labels, earlier studies, payer policies, physician searches, and patient records. FDA approval of Rezdiffra in March 2024 created the first U.S. drug pathway for adults with noncirrhotic NASH and moderate-to-advanced fibrosis. FDA estimated that about 6–8 million U.S. patients have NASH with moderate-to-advanced liver scarring, giving manufacturers and payers a defined treatment pool instead of a broad fatty-liver population.

 

Semaglutide changed the category again in August 2025 when FDA approved Wegovy for MASH with moderate-to-advanced scarring. Novo Nordisk entered the liver market with a GLP-1 therapy already embedded in obesity, diabetes, and cardiometabolic care. Madrigal created the first liver-directed pathway with Rezdiffra, while Novo Nordisk linked MASH treatment to weight loss, glucose control, cardiovascular-risk management, and metabolic clinic infrastructure. Drug competition is now developing around fibrosis stage, metabolic phenotype, payer rules, and treatment sequencing rather than around one single liver endpoint.

 

Fibrosis Defines the Treatable Population

The broad prevalence of MASLD substantially exceeds the population likely to receive drug treatment. A GBD 2023 analysis estimated around 1.3 billion people living with MASLD in 2023 and projected nearly 1.8 billion by 2050. MASLD creates the screening pool, but approved pharmacotherapy is concentrated in noncirrhotic MASH/NASH with F2–F3 fibrosis. Drug uptake depends on finding patients with clinically meaningful fibrosis before cirrhosis, not on treating every person with fatty liver.

A JAMA Network Open model estimated 14.9 million U.S. adults with MASH in 2020, rising to 18.4 million by 2030 and 23.2 million by 2050. MASH with clinically significant fibrosis, defined as F2 or higher, is projected to increase from 6.7 million people in 2020 to 11.7 million by 2050. Annual MASLD-related hepatocellular carcinoma cases are projected to rise from 11,483 in 2020–2025 to 22,440 in 2046–2050, while liver transplants are projected to increase from 1,717 to 6,720 per year. Advanced fibrosis, liver cancer, and transplant risk give payers a stronger reason to reimburse treatment than steatosis alone.

Type 2 diabetes represents a high-yield population for MASH case finding. A global meta-analysis reported pooled NASH prevalence of 37.3% among individuals with type 2 diabetes. Advanced fibrosis prevalence in patients with NAFLD and type 2 diabetes was estimated at 17.0%, although confidence intervals were wide due to heterogeneity in populations and diagnostic methods. Diabetes clinics, obesity practices, endocrinology services, and cardiometabolic programs are therefore important referral pathways for MASH evaluation, even when prescribing remains centered in hepatology or gastroenterology.

Diagnosis rates remain substantially below estimated disease prevalence. Published models commonly assume diagnosis rates near 10%, ranging from 3.3% to 14.3%. This gap limits near-term treatment uptake and revenue realization. Manufacturers can narrow it by supporting identification of F2–F3 patients through FIB-4 screening, elastography, specialist referral, and payer-accepted fibrosis documentation.

 

Rezdiffra Built the First Liver-Directed NASH Pathway

Rezdiffra gave physicians the first approved liver-directed therapy for noncirrhotic NASH with F2–F3 fibrosis. The oral once-daily profile gives Madrigal a practical advantage in a chronic disease setting, but prescription volume depends on fibrosis confirmation and payer acceptance. Early commercial adoption will be strongest where hepatology practices already use noninvasive fibrosis assessment and have systems to document eligibility.

MAESTRO-NASH provided the pivotal histologic efficacy data. At week 52, NASH resolution without fibrosis worsening was observed in 25.9% of patients receiving resmetirom 80 mg and 29.9% receiving 100 mg, versus 9.7% with placebo. At least one-stage fibrosis improvement without worsening steatohepatitis occurred in 24.2% and 25.9% of treated patients, versus 14.2% with placebo. These findings supported the first dedicated U.S. approval for NASH despite substantial unmet clinical need.

Madrigal’s execution risk sits in patient capture, not only product differentiation. Rezdiffra must move patients from primary care, diabetes clinics, obesity programs, and incidental liver-test findings into confirmed F2–F3 diagnosis. Payers are likely to require fibrosis evidence, specialist involvement, or noninvasive-test confirmation before approving therapy. A large epidemiologic population will not translate into treated volume unless physicians can stage disease quickly and document eligibility consistently.

Regulatory expansion has started outside the U.S. The EU granted conditional marketing authorization to Rezdiffra in August 2025. The UK MHRA authorized Rezdiffra in June 2026 for adults with noncirrhotic MASH and stage F2 or F3 fibrosis. National reimbursement decisions will decide how quickly these approvals become prescription volume. European adoption will likely begin in specialist hepatology centers with elastography access and established metabolic-liver disease pathways.

 

Semaglutide Pulls MASH Into Obesity and Diabetes Care

Wegovy’s approval changed MASH competition because semaglutide is already a major therapy in obesity and type 2 diabetes. Phase 3 ESSENCE data reported MASH resolution without worsening fibrosis in 62.9% of patients receiving semaglutide 2.4 mg versus 34.3% with placebo at week 72. Fibrosis reduction without worsening MASH occurred in 36.8% versus 22.4%. Trial design, duration, patient mix, and mechanism differ from Rezdiffra’s studies, so the percentages should not be treated as a head-to-head comparison.

Novo Nordisk brings a wider prescribing infrastructure than most liver-drug developers. Obesity physicians, endocrinologists, primary-care networks, cardiologists, and diabetes clinics already see many patients likely to have MASH. Wegovy’s liver indication allows those metabolic-care channels to become part of the MASH treatment funnel, although final staging and reimbursement may still require hepatology involvement.

Semaglutide’s broader metabolic profile changes payer and physician expectations. Weight reduction, glucose control, cardiovascular-risk positioning, and liver histology may be assessed together in patients with obesity or diabetes. Liver-directed agents may remain preferred for patients needing fibrosis-focused treatment, patients without obesity, patients unable to tolerate GLP-1 therapy, or patients already exposed to incretin therapy. Combination strategies may become commercially important if clinicians use GLP-1 therapy for metabolic risk and liver-directed treatment for fibrosis biology.

Semaglutide’s international regulatory expansion has been rapid. The EU conditionally authorized Kayshild in March 2026 for adults with noncirrhotic MASH and F2–F3 fibrosis, alongside diet and physical activity. Japan approved Wegovy in June 2026 for noncirrhotic MASH with moderate-to-advanced fibrosis, establishing semaglutide as the first approved MASH therapy in Japan. The UK MHRA approved Wegovy in July 2026 for adults with MASH and moderate-to-advanced fibrosis, with NHS access pending NICE appraisal.

 

Testing Capacity Decides Near-Term Treatment Conversion

MASH treatment is constrained by diagnosis, staging, and documentation. Many patients with MASLD remain in primary care, diabetes care, or obesity management without a confirmed fibrosis stage. Approved labels require physicians to identify F2–F3 patients while avoiding broad treatment of low-risk steatosis. Health systems without scalable noninvasive testing will struggle to convert prevalence into reimbursed prescriptions.

FIB-4, elastography, and specialist referral pathways are becoming part of the treatment economy. Payers need a consistent way to confirm eligibility, physicians need a practical workflow, and manufacturers need a route to diagnosed patients. Vibration-controlled transient elastography, MR-based tools, and blood-based fibrosis markers are gaining importance because liver biopsy is not scalable for a chronic metabolic disease affecting millions of patients.

FDA’s 2025 acceptance of a proposal to evaluate liver-stiffness measurement by vibration-controlled transient elastography as a potential reasonably likely surrogate endpoint in MASH trials could reduce dependence on repeated biopsy if qualification progresses. Drug developers would benefit from faster enrolment, lower endpoint variability, and more practical long-term monitoring. Clinical adoption still depends on accepted thresholds for treatment initiation, response assessment, and reimbursement.

Digital pathology is improving the clinical-trial side of the market. FDA qualified AIM-NASH in December 2025 as the first AI-based drug-development tool for MASH clinical trials. The tool assists pathologists in scoring steatosis, ballooning, lobular inflammation, and fibrosis, while final interpretation remains with the pathologist. Sponsors gain value if scoring variability falls, because histology inconsistency has contributed to high cost and operational risk in MASH development.

Lifestyle management continues to affect drug adoption because approved labels still require diet and exercise. A biopsy-based lifestyle study found that all participants losing at least 10% of body weight improved NAFLD activity score, 90% achieved NASH resolution, and 45% had fibrosis regression. Five-year bariatric-surgery data showed NASH resolution without worsening fibrosis in 84% of selected patients, with fibrosis improvement in about 70%. Payers may use these data to reinforce lifestyle requirements, while physicians may use drugs as part of structured metabolic-risk management rather than as stand-alone liver therapy.

 

Late-Stage Competition Is Moving Beyond One Mechanism

The availability of an approved therapy has not reduced pipeline activity. Multiple Phase 3 programs are testing whether MASH can support a multi-mechanism treatment ladder across incretin therapy, FGF21 analogues, PPAR agonism, thyroid-hormone receptor targeting, and combination regimens. Future competition will be judged by fibrosis response, MASH resolution, weight change, cardiometabolic benefit, tolerability, dosing burden, and eventual liver-event outcomes.

Tirzepatide is the most visible potential disruptor because it already has strong obesity and diabetes traction. In the 190-participant SYNERGY-NASH Phase 2 study, MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% of patients receiving tirzepatide 5 mg, 10 mg, and 15 mg, respectively, versus 10% with placebo. Fibrosis improvement without worsening MASH occurred in 55%, 51%, and 51% of treated patients, versus 30% with placebo. Lilly’s broader metabolic franchise gives tirzepatide a strong route into MASH if Phase 3 data support approval.

FGF21 analogues are competing for a differentiated liver-metabolic position. Akero’s efruxifermin is being evaluated in Phase 3 SYNCHRONY studies for noncirrhotic MASH and compensated cirrhosis. 89bio’s pegozafermin is in Phase 3 ENLIGHTEN studies for F2–F3 MASH and compensated cirrhosis, with noncirrhotic histology data expected later in development. FGF21 assets may appeal to physicians if they show strong fibrosis, lipid, liver-fat, and metabolic effects, but injectable administration and competition from GLP-1-based therapies will influence uptake.

PPAR and glucagon/GLP-1 strategies remain active. Inventiva’s lanifibranor Phase 3 NATiV3 trial is evaluating adults with NASH and F2–F3 fibrosis, supported by FDA Breakthrough Therapy and Fast Track designations. Boehringer Ingelheim’s survodutide entered Phase 3 LIVERAGE trials after FDA Breakthrough Therapy designation, with programs evaluating MASH and fibrosis improvement after 52 weeks and longer-term reduction in end-stage liver-disease risk. These products will need clear differentiation because approved competitors already cover liver-directed and GLP-1-based treatment positions.

 

Regional Adoption Will Depend on Access Rules

The U.S. remains the highest-value NASH treatment market because two approved therapies now address F2–F3 disease, the eligible patient pool is large, and obesity-diabetes networks can feed case finding. Insurers will strongly influence uptake through prior authorization, fibrosis-stage documentation, specialist requirements, and rules around lifestyle management. Rezdiffra may move through hepatology-led pathways, while Wegovy can enter through metabolic-care networks when liver eligibility is confirmed.

Europe has regulatory momentum but country-level reimbursement will control adoption speed. Rezdiffra and Kayshild have EU authorizations, and the UK has authorized both Rezdiffra and Wegovy. NICE decisions will shape NHS access and influence pricing expectations in other payer systems. Early European uptake will likely concentrate in hepatology centers with elastography capacity, obesity-care links, and formal metabolic-liver disease protocols.

Japan’s approval of Wegovy gives Asia a major MASH regulatory milestone. Japan’s aging population, diabetes burden, and growing noninvasive diagnostic capacity create a favorable setting for semaglutide-based MASH treatment. Broader Asian adoption will vary by reimbursement, obesity-treatment policy, specialist access, and whether health systems prioritize fibrosis screening in high-risk metabolic populations.

India has a distinct treatment and access structure. Saroglitazar received Indian regulatory approval for NASH in March 2020. Zydus expanded commercial reach through co-marketing and licensing agreements, including arrangements with Torrent and Lupin for chronic liver disease treatment. Morepen Laboratories received CDSCO committee clearance to conduct bioequivalence studies for resmetirom tablets, signaling domestic preparation around the newer liver-directed drug class. India’s market will likely balance locally available products, affordability, diabetes-linked screening, and gradual adoption of global MASH standards.

 

Company Positioning Now Depends on Patient Capture

Madrigal owns the first dedicated liver-directed franchise through Rezdiffra. Its advantage sits in oral dosing, first-mover hepatology adoption, and a label built around F2–F3 fibrosis. Growth depends on expanding prescriber confidence, securing payer coverage, supporting noninvasive staging workflows, and defending against metabolic therapies with broader patient familiarity.

Novo Nordisk has pushed MASH into the GLP-1 era. Wegovy’s liver indication gives the company access to MASH patients already moving through obesity and diabetes care. Supply planning, payer controls, tolerability management, and obesity-drug pricing debates will influence how quickly semaglutide’s liver approval converts into routine MASH use.

Eli Lilly is the most important future incretin competitor because tirzepatide combines obesity, diabetes, and promising MASH histology data. Akero, 89bio, Inventiva, and Boehringer Ingelheim are competing for positions around fibrosis, liver-event reduction, cirrhosis-adjacent disease, and metabolic differentiation. Late-stage results will decide whether MASH remains a two-product category or becomes a segmented chronic-disease market with liver-directed, incretin, FGF21, PPAR, and combination options.

 

Analyst View

NASH treatment is now a fibrosis-confirmed prescription market. Broad MASLD prevalence creates the screening pool, while F2–F3 MASH defines the reimbursable treatment population for current approvals. Drugmakers will compete less on disease awareness alone and more on their ability to help clinicians identify, stage, treat, and monitor eligible patients.

Rezdiffra created the first liver-directed commercial pathway. Wegovy extended MASH into obesity and diabetes care. Tirzepatide, efruxifermin, pegozafermin, lanifibranor, and survodutide will determine how crowded the treatment ladder becomes over the next few years.

The most useful market indicators are FIB-4 use, elastography access, payer criteria for F2–F3 confirmation, hepatology referral capacity, Rezdiffra uptake, Wegovy reimbursement for MASH, NICE decisions, GLP-1 supply, tirzepatide Phase 3 outcomes, FGF21 readouts, and progress on noninvasive endpoints. Companies that control patient identification and treatment routing will have stronger positioning than companies relying only on positive biopsy endpoints.

 

Non-Alcoholic Steatohepatitis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 8.75 Billion
Revenue Forecast in 2032	USD 46.87 Billion
Overall Growth Rate	CAGR of 27.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Disease Stage, By Route of Administration, By Treatment Setting, By Patient Risk Group, By Distribution Channel, By Geography
By Drug Class	THR-β Agonists, GLP-1 Receptor Agonists, Dual Incretin Therapies, FGF21 Analogues, PPAR Agonists, Glucagon/GLP-1 Dual Agonists, Supportive Metabolic Therapies
By Disease Stage	Noncirrhotic MASH/NASH with F2 Fibrosis, Noncirrhotic MASH/NASH with F3 Fibrosis, Compensated Cirrhosis, High-Risk MASLD Patients Under Evaluation
By Route of Administration	Oral Therapies, Injectable Therapies
By Treatment Setting	Hepatology Clinics, Gastroenterology Clinics, Endocrinology & Diabetes Clinics, Obesity & Weight-Management Centers, Hospitals, Specialty Liver Centers
By Patient Risk Group	Patients with Type 2 Diabetes, Patients with Obesity, Patients with Moderate-to-Advanced Fibrosis, Patients with Cardiometabolic Risk, Patients Referred Through Abnormal Liver Tests
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	First approved prescription-drug pathways for NASH/MASH, rising F2–F3 fibrosis diagnosis, GLP-1 expansion into liver care, growing diabetes and obesity-linked screening, payer focus on fibrosis-defined treatment eligibility, wider use of FIB-4 and elastography testing
Customization Option	Available upon request